title: Neuroleptic malignant syndrome: a case that may shed new light into the etiology and treatment.
authors.forename: Aysegul
authors.initials: A
authors.lastname: Yildiz
authors.forename: Tunc
authors.initials: T
authors.lastname: Alkin
authors.forename: Aysegul
authors.initials: A
authors.lastname: Ozerdem
authors.forename: Kemal
authors.initials: K
authors.lastname: Sagduyu
authors.forename: Christina M
authors.initials: CM
authors.lastname: Demopulos
mesh_terms: D000209:Acute-Phase Proteins / Q000032:analysis; D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001971:Bromocriptine / Q000627:therapeutic use; D003006:Clopenthixol / Q000009:adverse effects*; D018491:Dopamine Agonists / Q000627:therapeutic use; D004565:Electroconvulsive Therapy; D005260:Female; D006801:Humans; D009459:Neuroleptic Malignant Syndrome / Q000209:etiology* / Q000628:therapy*; D013881:Thioridazine / Q000009:adverse effects*
chemical_list: D000209:Acute-Phase Proteins; D014150:Antipsychotic Agents; D018491:Dopamine Agonists; D001971:Bromocriptine; D003006:Clopenthixol; D013881:Thioridazine